To date, there has only been one study (performed on the same cohort of patients as this study) which has investigated the role of GLUT1 as a biomarker in esophageal adenocarcinoma, and positive expression was associated with a poorer prognosis [17]. This evidence concerns the gene SLC2A1 and esophageal adenocarcinoma.